Prenetics Global Limited
NASDAQ:PREMedical - Diagnostics & Research
+$0.43 today
- Market cap
- $185.61M
- Beta
- 0.24
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$4.18
Volume 1.58M
Average 0.22M
PRE Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Prenetics Global LimitedNASDAQ: PRE
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization outflow grows to $184K
Q1 FY2026 depreciation & amortization was $184K, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $3.97M. Over 3 fiscal years it compounded at -20.6% a year.
Context
- Depreciation & amortization amounted to 4.1% of revenue in FY2025, down 15.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $184K or moves back toward the trailing-twelve-month quarterly average of $991.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 3.78M USD
- Year-over-year change
- -36.2%
- 4-year CAGR
- -15.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.78M | -36.2% |
| FY2024 | 2024-12-31 | 5.93M | -23.9% |
| FY2023 | 2023-12-31 | 7.79M | +3.3% |
| FY2022 | 2022-12-31 | 7.54M | +2.7% |
| FY2021 | 2021-12-31 | 7.35M | — |
Depreciation & Amortization vs competitors
How PRE compares with its peers on the latest reported figures
- PRE's LTM Mar 2026 depreciation & amortization of $3.97M is the 5th largest of the 11 companies compared; the peer median is $3.56M.
- Depreciation & amortization amounts to 3.5% of revenue for PRE, versus a peer median of 8.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.86M | -9.2% | -91.3% | 8.7% | |
| LTM Mar 2026 | $6.75M | +171.1% | -20.0% | 8.6% | |
| LTM Mar 2026 | $6.56M | -25.2% | -28.2% | 19.0% | |
| LTM Mar 2026 | $4.68M | +4.5% | +24.0% | 14.5% | |
| LTM Mar 2026 | $3.97M | — | -20.6% | 3.5% | |
ATLNAtlantic International Corp. | LTM Dec 2025 | $3.82M | -30.9% | +33.8% | 0.9% |
| LTM Mar 2026 | $3.3M | +36.1% | +28.1% | 2.2% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $2.34M | +35.9% | -25.1% | 119.9% |
| LTM Mar 2026 | $1.61M | +16.3% | +19.7% | 54.5% | |
| LTM Mar 2026 | $589K | -20.5% | +16.3% | 1.3% | |
| LTM Mar 2026 | $499.37K | -27.3% | -29.2% | 2.6% | |
| Peer median (excluding PRE) | $3.56M | -2.3% | -1.9% | 8.7% | |
Competitors are the stored peer set for PRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (174.02M) | (190.45M) | (64.78M) | (49.81M) | (52.7M) |
| Depreciation & Amortization | 7.35M | 7.54M | 7.79M | 5.93M | 3.78M |
| Deferred Income Tax | 3.73M | 7.15M | (385.84K) | (7.87M) | 0 |
| Stock-Based Compensation | 22.49M | 31.58M | 10.59M | 11.98M | 0 |
| Change in Working Capital | (6.59M) | (33.76M) | 24.21M | 1.97M | 6.62M |
| Accounts Receivables | (24.06M) | 6.97M | 37.63M | (428K) | (529K) |
| Inventory | (2.33M) | 1.26M | (1.73M) | 1.32M | (3.38M) |
| Accounts Payables | (3.46M) | (2.63M) | (5.62M) | (4.68M) | 4.91M |
| Other Working Capital | 23.26M | (39.36M) | (6.08M) | 5.75M | 5.62M |
| Other Non-Cash Items | 160.45M | 192.46M | 8.8M | 8.93M | 20.48M |
| Operating Cash Flow | 13.42M | 14.51M | (13.76M) | (28.87M) | (21.81M) |
| Capital Expenditures | (11.41M) | (6.34M) | (911.81K) | (1.07M) | (208K) |
| Acquisitions (Net) | 0 | (3.42M) | 0 | 21.65M | 37.78M |
| Purchases of Investments | (10M) | (39.92M) | (26M) | (129K) | (20M) |
| Sales of Investments | 0 | 3M | 19.92M | 16M | 0 |
| Other Investing Activities | (3.47M) | 531.99K | (76.52M) | 2.02M | 1,000K |
| Investing Cash Flow | (22.02M) | (46.14M) | (82.95M) | 38.54M | (35.79M) |
| Debt Repayment | (1.3M) | (1.88M) | (3.23M) | (2.56M) | 40.15M |
| Common Stock Issued | 0 | 116.86K | 2.17K | 0 | 2K |
| Common Stock Repurchased | 0 | (661.52K) | (1.23M) | (577K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.65M | 145.86M | (241.5K) | (203K) | (2.61M) |
| Financing Cash Flow | 29.32M | 143.32M | (4.7M) | (3.34M) | 37.54M |
| Effect of Forex Changes | 87.21K | (317.47K) | 467.93K | 221K | (65K) |
| Net Change in Cash | 20.8M | 111.37M | (100.95M) | 6.55M | (20.12M) |
| Free Cash Flow | 2M | 8.17M | (14.68M) | (29.94M) | (22.02M) |
Prenetics Global Limited
NASDAQ:PRE
Intrinsic Alpha fair value
Locked
Current Price
$10.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.